Senior Machine Learning Scientist at Freenome

Brisbane, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

BiotechnologyIndustries

Requirements

Strong knowledge of artificial intelligence (AI), including machine learning (ML) fundamentals and extensive experience with deep learning (DL) methods
Track record of successfully using ML/DL methods to answer complex research questions
Experience with building and deploying machine learning models
Ability to thrive in a highly cross-functional environment

Responsibilities

Developing algorithms for early, blood-based detection tests for cancer
Building on a foundation of ML/DL and statistical skills to develop models for identifying molecular signals from blood
Working with other teams to design and drive research experiments

Skills

Machine Learning

Deep Learning

Artificial Intelligence

Genomics

Computational Biology

Immunology

Molecular Biology

Freenome

Biotechnology company for early cancer detection

About Freenome

Freenome focuses on improving cancer detection through advanced blood tests. The company uses a multiomics approach, analyzing various biological data types, including genomics and proteomics, to find cancer markers in blood samples. This method allows for non-invasive early detection of cancer, which is crucial for effective treatment. Freenome differentiates itself from competitors by its unique combination of data analysis techniques and its commitment to clinical trials and research collaborations. The company's goal is to enhance cancer diagnostics and make early detection accessible to healthcare providers and patients, ultimately aiming to save lives through timely intervention.

San Francisco, CaliforniaHeadquarters

2014Year Founded

$1,032.6MTotal Funding

LATE_VCCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Competitive market-based salaries

Annual bonus opportunities

Relocation packages

Medical, dental, & vision coverage

401k

Wellness programs

Equity

PTO

Risks

Employee layoffs may affect morale and innovation efforts.

Integration of Oncimmune Ltd. could divert focus from core projects.

Competitive landscape in cancer detection may impact Freenome's market share.

Differentiation

Freenome uses a unique multiomics approach for early cancer detection.

The company focuses on non-invasive blood tests for cancer screening.

Freenome's platform designs personalized health conditions based on cell-free genome analysis.

Upsides

Recent $254 million funding boosts clinical programs and platform expansion.

Partnership with Walgreens enhances clinical trial diversity and patient recruitment.

PROACT LUNG study positions Freenome as a leader in lung cancer diagnostics.

Land your dream remote job 3x faster with AI

Try Jobo Free